Patent application number | Description | Published |
20100041713 | SUBSTITUTED AMINOTETRALINES - The invention is concerned with the compounds of formula I: | 02-18-2010 |
20100041714 | BI-ARYL AMINOTETRALINES - The invention is concerned with the compounds of formula I: | 02-18-2010 |
20100041760 | MONOARYL AMINOTETRALINES - The invention is concerned with the compounds of formula I: | 02-18-2010 |
20100125058 | NAPHTHYLACETIC ACIDS - The invention is concerned with the compounds of formula I: | 05-20-2010 |
20100125061 | NAPHTHYLACETIC ACIDS - The invention is concerned with the compounds of formula I: | 05-20-2010 |
20100137250 | NAPHTHYLACETIC ACIDS - The invention is concerned with the compounds of formula I: | 06-03-2010 |
20110124686 | SULTAM DERIVATIVES - The present invention relates to compounds according to formula 1, | 05-26-2011 |
20110144105 | AZAINDOLE GLUCOKINASE ACTIVATORS - Provided herein are compounds of the formula (I): | 06-16-2011 |
20120046306 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists - There are provided compounds of the general formula | 02-23-2012 |
20120095053 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS - The invention is concerned with the compounds of formula I: | 04-19-2012 |
20120101131 | Aminotetrahydroindazoloacetic Acids - The invention is concerned with the compounds of formula I: | 04-26-2012 |
20120230951 | ANTIVIRAL COMPOUNDS - The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 09-13-2012 |
20120295885 | INHIBITORS OF BRUTON'S TYROSINE KINASE - This application discloses compounds according to generic Formula I: | 11-22-2012 |
20120309796 | BENZOCYCLOHEPTENE ACETIC ACIDS - Provided herein are compounds of the formula (I): | 12-06-2012 |
20120328565 | ANTIVIRAL COMPOUNDS - The present invention discloses compounds of Formula I | 12-27-2012 |
20130018043 | AMINOMETHYL QUINOLONE COMPOUNDS - The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: | 01-17-2013 |
20130102600 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease - The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 04-25-2013 |
20130102601 | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease - The present invention relates to a compound having the general formula II, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 04-25-2013 |
20130116322 | ALKENYL NAPHTHYLACETIC ACIDS - The invention is concerned with the compounds of formula (I): | 05-09-2013 |
20130150407 | PIPERIDINYL NAPHTHYLACETIC ACIDS - The invention is concerned with the compounds of formula (I): | 06-13-2013 |
20130225588 | SUBSTITUTED NAPHTHYLACETIC ACIDS - The invention is concerned with the compounds of formula (I): | 08-29-2013 |
20130317021 | HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE - The present invention relates to a compound having the general formula (C), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 11-28-2013 |
20130317022 | 7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE - The present invention relates to a compound having the general formula (A), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 11-28-2013 |
20140038990 | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease - The present invention relates to a compound having the general formula (Di), (Dii), or (Diii), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 02-06-2014 |
20140194431 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE - The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 07-10-2014 |
20140194432 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE - The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 07-10-2014 |
20140194476 | PYRIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELORIATION OR PREVENTION OF A VIRAL DISEASE - The present invention relates to a compound having the general formula (II), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 07-10-2014 |
20140255344 | Antiviral Compounds - The present invention discloses compounds of Formulae I and II, wherein the variables in Formulae I and II are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formulae I and II in the treatment of HCV infection. | 09-11-2014 |